Martín Igor Gómez-Randulfe, Locum Consultant in Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Happy to share our new paper on second-line carboplatin+pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC.
International multicentre cohort. Main messages:
- About one third of patients respond
- PFS aligns with prior trial signals
- Median OS around 9 months in routine practice
- Toxicity is meaningful and dose adjustments are common
Chemotherapy still benefits a subset of patients, although the effect size is modest. This is important to keep in mind when considering new combination regimens or sequencing strategies.”
Title: Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
Authors: Igor Gomez-Randulfe, Federico Monaca, Ornella Cantale, Maria Lucia Reale, Loredana Mrak, Lodovica Zullo, Sofia Silva Diaz, Marta Zaragoza Bueno, Marya Alejandra Maridueña Moreno, Charlotte Davis, Samantha Cox, Daniel Lee, Riyaz Shah, Tom Geldart, Javier Baena, Jose Carlos Benitez, M. A. Rosario Garcia Campelo, Jordi Remon, David Planchard, Domenico Galetta, Marcello Tiseo, Diego Cortinovis, Giulio Metro, Emilio Bria, Francesco Passiglia, Silvia Novello, Raffaele Califano
Read the Full Article on Lung Cancer
More posts featuring Martín Igor Gómez-Randulfe.